211053-50-8

Basic information

• Product Name: 3(S)-HYDROXYMETHYLMORPHOLINE
• Synonyms: 3(S)-HYDROXYMETHYLMORPHOLINE;(S)-3-Hydroxymethylmorpholine;(S)-morpholin-3-ylmethanol;3-Morpholinemethanol, (3S)-;(3S)-morpholin-3-ylmethanol;(3S)-3-Morpholinemethanol;(3S)-3-Morpholinemethanol,99%e.e.
• CAS NO: 211053-50-8
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.15
• Product Categories: pharmacetical
• Mol File: 211053-50-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 112 °C
• Boiling Point: 218.3 °C at 760 mmHg
• Flash Point: 85.9 °C
• Appearance: /
• Density: 1.045 g/cm³
• Vapor Pressure: 0.0268mmHg at 25°C
• Refractive Index: 1.441
• Storage Temp.: 2-8°C
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 3(S)-HYDROXYMETHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3(S)-HYDROXYMETHYLMORPHOLINE(211053-50-8)
• EPA Substance Registry System: 3(S)-HYDROXYMETHYLMORPHOLINE(211053-50-8)

Safety Data

• RIDADR: 3261
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 211053-50-8(Hazardous Substances Data)

Usage

Uses

(S)-3-Hydroxymethylmorpholine is a chemical reagent used in the synthesis of Aurora kinase inhibitors, used for their anti-tumor activity. Also used in the preparation of human epidermal growth factor receptor 1 & 2 kinase inhbitors in the treatment of solid tumors.

InChI:InChI=1/C5H11NO2/c7-3-5-4-8-2-1-6-5/h5-7H,1-4H2/t5-/m0/s1

Upstream product

• 885321-34-6 (R)-3-(tert-butyldiphenylsilyloxymethyl)morpholine 
• 101376-25-4 (S)-4-benzyl-3-(hydroxymethyl)morpholine 
• 106973-36-8 (3R)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 

Downstream Products

• 913719-06-9 (3S)-3-(3-phenylprop-2-yn-1-yl)morpholine 
• 1373488-37-9 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide 
• 869681-70-9 (R)-morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 
• 885321-46-0 (R)-methyl N-tert-butoxycarbonylmorpholine-3-carboxylate 
• 714971-28-5 (S)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS

A series of fused bicyclic thiazole and thiophene derivatives which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, and in the 4-position by hydroxy, oxo or an amine moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. (I)

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.